



## Gubra capital increase in connection with exercise of warrants

Gubra A/S ("Gubra" or the "Company") has increased its share capital by 85,872 shares (corresponding to a nominal value for DKK 85,872) as a result of the exercise of a corresponding number of warrants granted to Management members of the Company in 2023.

The new shares are subscribed for in cash at DKK 37.3917 per share (the exercise price was in accordance with terms and conditions for the warrants lowered by DKK 61.2 per share following the extraordinary dividend in 2025 which warrant holders were not entitled to). The total proceeds to Gubra in connection with the capital increase amount to DKK 3,210,900.06.

The new shares (i) are ordinary shares without any special rights and are negotiable instruments, (ii) give the right to dividends and other rights in relation to Gubra as of the date of issuance and (iii) are expected to be admitted to trading on Nasdaq Copenhagen as soon as possible.

After the capital increase, Gubra's share capital totals 16,435,575 shares. Each share carries one vote.

### Contacts at Gubra

Media: Marianne Thomas ([mho@gubra.dk](mailto:mho@gubra.dk), +45 2483 2663)

Investors: Kristian Borbos ([kbo@gubra.dk](mailto:kbo@gubra.dk), +45 3080 8035) and Adam Lange ([adl@gubra.dk](mailto:adl@gubra.dk), +45 6646 1589)

### About Gubra

Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra's activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around \$400 million) in 2025. See [www.gubra.dk](http://www.gubra.dk) for more information.